China’s First National Medical Insurance Standard: £145bn Opportunity for UK Life Sciences
Insight from Excellence First Enterprise Consultancy (EFEC) Disclaimer: This article is for general information only and does not constitute professional, financial, or legal advice. Market projections are based on current data and subject to change.
Strategic momentum: Building UK–China bridges in life sciences through Wuhan
Disclaimer: This article reflects EFEC’s views and insights based on information available as of August 2025. While believed to be accurate, some data are estimates or projections and may change over time. It is provided for general information only and does not constitute professional, investment, or commercial advice.
Insights from the UK Life Sciences Start-up Report 2025: Building bridges with China for mutual growth
Disclaimer: This article is for informational purposes only and reflects the author’s independent observations on the UK life sciences sector and international collaboration opportunities. It does not constitute investment advice.
Bridging ambition and reality: How bi-cultural talent ecosystems can unlock the next wave of Chinese investment in the UK
Disclaimer: This article offers general, evidence-based insights for business professionals and policymakers. It is not legal or investment advice. Readers should consult primary sources before acting on any information provided.
UK perspective: Harnessing the power of global collaboration in Precision Oncology
Disclaimer:The views expressed in this article reflect the professional perspective and experience of Excellence First Enterprise Consultancy Ltd (EFEC). This content is intended for informational purposes only and does not constitute commercial endorsement, medical advice, or solicitation of investment. EFEC is committed to providing balanced, objective commentary and supports open,…
Navigating the UK life sciences talent landscape in 2025: Growth opportunities, key challenges and strategies for integrating Chinese expertise
Disclaimer: This article is intended for industry professionals and provides general educational information only. It does not promote specific products or constitute medical advice.Market OverviewThe UK life sciences sector remains a cornerstone of the national economy, employing around 300,000 people and contributing approximately £100 billion annually. In 2025, the market shows signs of…
Chinese biopharma out-licensing: Ushering in a new era for UK-China collaboration in 2025
Disclaimer: This article is intended for industry professionals and provides general educational information only. It does not promote specific products or constitute medical advice.Introduction
Turning trade tensions into opportunity: How UK businesses can lead in the medical device sector
Disclaimer: This article is intended for industry professionals and provides general educational information only. It does not promote specific products or constitute medical advice.
Building lasting value: Why UK healthtech needs an ecosystem approach for China
As the global healthtech landscape continues to evolve, China stands out not only for its scale and speed but also for the complexity and dynamism of its healthcare ecosystem. For UK innovators, the opportunity is immense—but so are the challenges. The real question is not just how to enter the Chinese market, but how to build a sustainable, trusted presence that delivers long-term value.
A £14.5 Billion Opening: How UK life sciences firms can lead China’s healthcare transformation
On 2 July 2025, China’s Ministry of Finance, National Health Commission, and National Disease Control Administration jointly announced a RMB 20.92 billion (£14.5 billion) Major Public Health Service Subsidy Fund for 2025. This signals a bold continuation of healthcare system modernisation, including a 5.3% increase in per capita public health funding to RMB 99.
A Chinese perspective on England’s “Fit for the Future” NHS plan
In July 2025, England launched its ambitious “Fit for the Future” strategy—a 10-year vision to transform the National Health Service (NHS). By shifting care closer to communities, accelerating digital transformation, and prioritising prevention, the plan addresses the urgent challenges of an ageing population, chronic disease, and hospital pressures. These priorities are not unique to the UK;…
Leading Beyond Boundaries: EFEC’s 2025 Leadership Series – Session 3 Report
Context: A Transformative Leadership JourneyIn 2025, Excellence First Enterprise Consultancy (EFEC) launched the “Leading Beyond Boundaries” series in partnership with the Pudong Institute for Educational Research & Development.
Reconnecting innovation: Cambridge hosts delegation from Shanghai Lingang
On 20th June 2025, Cambridge welcomed a delegation from Shanghai Lingang New Area Aviation Industry Development Co., Ltd. for a constructive and forward-looking exchange. Organised by Excellence First Enterprise Consultancy (EFEC), the meeting represented a measured but important step in renewing dialogue between two internationally engaged innovation communities.
Synthetic biology in China’s Yangtze River Delta: Opportunities & insights for UK–China collaboration
By Excellence First Enterprise Consultancy Ltd.
UK-China Life Sciences Forum in London: Fostering practical collaboration
On 10 June 2025, the “Sino-UK Pharmaceutical Cooperation Partnering Conference” convened at the Millennium Gloucester Hotel in London, providing a valuable forum for professionals and organisations from both the UK and China to explore new opportunities in life sciences and healthcare innovation. Hosted by China Medical City (CMC) of Taizhou, the event welcomed a diverse group of government…
EFEC’s role in advancing UK-China life sciences collaboration at MTI Expo 2025
Excellence First Enterprise Consultancy Ltd (EFEC) continues to play a pivotal role in bridging the UK and China across education, talent, and innovation ecosystems, with a particular focus on life sciences and healthcare technology. At the 2025 UK Medical Technology Innovation Expo (MTI Expo 2025), EFEC’s activities underscored its position as a key facilitator of cross-border innovation and…
China’s AI healthcare revolution: What UK partners should know
In 2025, China’s healthcare sector is undergoing a profound transformation powered by artificial intelligence (AI) and, most notably, the emergence of AI Agents—autonomous, intelligent programmes built on large language models (LLMs). This revolution is reshaping clinical practice, hospital management, and patient care at a scale and speed rarely seen globally. For UK partners and stakeholders,…
Exploring new approaches to educational leadership in Shanghai Pudong
A Collaborative Initiative by EFEC and Pudong Institute of Education Development and Research.
China at Now - An EFEC insight for the UK life sciences community
China’s life sciences sector is undergoing a profound transformation, driven by rapid innovation, deepening global integration, and significant advancements in biopharmaceuticals and medical devices.
EFEC explores UK-China Life Sciences Synergies at VBEF 2025
At Excellence First Enterprise Consultancy (EFEC), we have dedicated 19 years to forging successful UK-China partnerships, now connecting UK life sciences organisations with opportunities in China and preparing Chinese firms for success in the UK, growing together through shared innovation.
Why the UK life sciences sector must collaborate with China: Insights from Cedrik Neike’s perspective
Cedrik Neike, Managing Board Member of Siemens AG and CEO of Siemens Digital Industries, has provided a compelling perspective on the indispensable role China plays in maintaining the global competitiveness of German industry.
EFEC insight: China’s 91st CMEF and the future of global medical innovation
The 91st China International Medical Equipment Fair (CMEF), held from 8–11 April 2025 in Shanghai, underscored China’s growing prominence in medical technology and innovation. With nearly 5,000 companies from over 30 countries showcasing thousands of cutting-edge products, CMEF solidified its status as a global barometer for the medical device industry.
The end of Sino-American SK: What it means for UK businesses eyeing China
A 40-Year Chapter Closes, A New Era BeginsThe complete exit of Chinese shareholders from Sino-American Tianjin SmithKline (中美史克) marks the end of one of China’s most iconic joint ventures. With Haleon (spun off from GSK and Pfizer) now holding 100% ownership, this is not just a business transaction but a symbolic closure of the “golden age” of Sino-foreign pharmaceutical joint ventures that…
EFEC Insight: Empowering Chinese Talent for UK Economic Prosperity and Global Impact
The evolving landscape of Chinese study abroad - China’s study abroad preferences are shifting dramatically, moving away from the prestige of American Ivy League universities towards education that delivers practical value.
Shanghai Zeolym High School at One: Exploring Education’s Future in an AI World
On 8 April 2025, Shanghai Zeolym High School marked its first anniversary since its founding in 2024. This innovative, co-educational institution, offering both day and boarding programmes, has quickly established itself as a forward-thinking school dedicated to holistic education.